Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
187.86
+5.24 (2.87%)
Feb 21, 2025, 4:00 PM EST - Market closed
Krystal Biotech Employees
Krystal Biotech had 229 employees as of February 1, 2024. The number of employees increased by 19 or 9.05% compared to the previous year.
Employees
229
Change (1Y)
19
Growth (1Y)
9.05%
Revenue / Employee
$1,268,624
Profits / Employee
$389,341
Market Cap
5.41B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 1, 2024 | 229 | 19 | 9.05% |
Feb 20, 2023 | 210 | 91 | 76.47% |
Feb 18, 2022 | 119 | 44 | 58.67% |
Feb 19, 2021 | 75 | 22 | 41.51% |
Feb 28, 2020 | 53 | 16 | 43.24% |
Feb 28, 2019 | 37 | 25 | 208.33% |
Jan 31, 2018 | 12 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
KRYS News
- 1 day ago - Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus - Seeking Alpha
- 3 days ago - Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewsWire
- 4 days ago - 20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset' - Market Watch
- 5 weeks ago - Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy - Seeking Alpha
- 2 months ago - Krystal Biotech Announces Early Evidence of Monotherapy Activity in Heavily Pre-Treated Patients with Advanced Non-Small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - Krystal Biotech Provides Update on EMA's Ongoing Regulatory Review of B-VEC for Dystrophic Epidermolysis Bullosa - GlobeNewsWire